KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Investing Activities (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Cash from Investing Activities for 6 consecutive years, with -$36.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 193.71% year-over-year to -$36.8 million, compared with a TTM value of -$32.8 million through Dec 2025, down 183.46%, and an annual FY2025 reading of -$32.8 million, down 183.46% over the prior year.
  • Cash from Investing Activities was -$36.8 million for Q4 2025 at Aurinia Pharmaceuticals, down from -$13.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $49.2 million in Q1 2024 and bottomed at -$67.2 million in Q1 2021.
  • Average Cash from Investing Activities over 5 years is -$8.2 million, with a median of -$8.4 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities surged 2631.8% in 2022, then crashed 588.69% in 2024.
  • Year by year, Cash from Investing Activities stood at -$5.5 million in 2021, then soared by 45.0% to -$3.0 million in 2022, then tumbled by 107.32% to -$6.3 million in 2023, then surged by 726.87% to $39.2 million in 2024, then tumbled by 193.71% to -$36.8 million in 2025.
  • Business Quant data shows Cash from Investing Activities for AUPH at -$36.8 million in Q4 2025, -$13.8 million in Q3 2025, and -$13.3 million in Q2 2025.